and the Groupe Liè geois d'Etude des Virus Hé patotropes* Background Current treatments of chronic hepatitis C virus (HCV) are effective, but expensive and susceptible to induce significant side effects.
Introduction
Hepatitis C virus (HCV) is an important cause of chronic liver disease worldwide with a significant global mortality and morbidity. The World Health Organization estimates that about 3% of the world population is currently infected with HCV. In the United States, the estimated prevalence is 1.8% [1] . In Europe, among blood donors, the prevalence of HCV ranged from very low (< 0.1%) in the United Kingdom and Scandinavia, to low (0.1-0.5%) in the rest of Western Europe and moderate (0.6%) in Southern Europe [2] . In a sample of the general population in Belgium, the seroprevalence was 0.87% [3] . More than 70% of newly infected patients progress to chronic infection with its attendant complications of cirrhosis, liver failure and hepatocellular carcinoma. Furthermore, the health-related quality of life is sig-nificantly compromised in persons with chronic HCV, compared with the general population [4] . At present, the management of patients with hepatitis C largely focuses on combination antiviral treatment using a 24week or 48-week course of peginterferon and ribavirin [5] . These therapies proved to be effective. They are susceptible, however, to inducing significant adverse effects. In addition, they are expensive, and entail a substantial socioeconomic burden. It has been shown that the therapy was cost-effective, in particular, in US [6] , Spanish [7] , German [8] and Belgian settings [9] [10] [11] . Beyond the problem of the cost-effectiveness ratio, however, the global cost estimation of a treatment for a country depends on the number of patients actually treated per year. There is a huge discrepancy between the number of patients that could be potentially treated in regards of the disease prevalence and the number of patients that are actually treated. For Belgium, for example, only around 1000 patients are treated every year for an estimated population of about 90 000 infected persons. It has been suggested that a large number of patients are still unaware of their seropositivity. Furthermore, under-reporting by healthcare professionals is common, and many high-risk individuals do not have easy access to health care. Another explanation is that only a small proportion of patients that are seeking medical care are eventually treated. In the United States, it has been shown in the Veterans' population infected with HCV that 30% only of referred patients were considered eligible for therapy [12, 13] . In this population, the most common contraindication was psychosocial factors [12] . Although the findings in HCV-infected US Veterans may not be directly applicable to other HCV populations (because they are more likely than HCVinfected US non-Veterans to have a history of alcoholism, active substance abuse, post-traumatic stress disorder and antidepressant therapy [14] ), a few studies in the general population in the United States also reported that many patients were not eligible for therapy [15] [16] [17] . To date, such figures are not available for Europe. We therefore investigated the overall antiviral treatment rate and the reasons for non-treatment in a population of HCVinfected patients in Belgium.
Methods
From 1992 to 2003, the Centre for Molecular Diagnosis of Liège, Belgium has depicted 1726 viraemic HCV patients (i.e. those found positive for HCV-RNA by polymerase chain reaction) [18] . From that database, we reviewed the charts of patients who presented to the Academic Hospital Sart Tilman, Liège, Belgium, between 1996 and 2003, for an initial appointment with the same hepatologist. The year 1996 was chosen because effective therapies combining interferon and ribavirin became available at that time in this hospital. Only patients for whom the polymerase chain reaction was requested by this hepatologist were taken into account in the analysis. This attitude was taken to reduce the potential bias of an over-assessment of the treatment rate due to a referring of patients initially evaluated in another centre and sent to the academic hospital in order to initiate the therapy. All patients were evaluated by the same hepatologist, who decided to treat or not to treat on the basis of classical guidelines. For all patients, the following information was gathered: demographics, medical history, modes of contamination and viral genotype. For treated patients, the rate of sustained viral response, of relapse after the end of therapy or of non-response was assessed, as well as the rate of premature discontinuation of therapy. For each untreated patient, we documented reasons for not initiating therapy such as medical contraindications, mood disorders, current pregnancy or desire of pregnancy, refusal, non-adherence to medical evaluation (defined as missing two or more clinic appointments or not attending the appointment for liver biopsy) and normal alanine aminotransferase (ALT) levels.
This study was approved by the Ethics Committee of the University of Liège, Belgium.
Statistical analysis
Comparisons were analysed by either the chi-square test or the Student's t-test. The statistical results were considered to be significant at the level of 5%.
Results
The files of 299 patients were reviewed. The mean age was 43.1 ± 15.6 years; 157 patients (53%) were male. Most patients (274 patients) were Caucasians (92%), 22 patients (7%) were Africans and three patients (1%) were Asians.
Risk factors for HCV acquisition were transfusion before 1992 for 127 patients (43%), intravenous drug use for 66 patients (22%), needle-stick injury for four patients (1%), sexual for three patients (1%) and of unknown origin for 102 patients (33%).
Genotypes were determined in 134 patients. Genotype 1 was the most common (89 patients, 66%). Genotype 2 was found in 13 patients (10%), genotype 3 in 16 patients (12%), genotype 4 in 13 patients (10%) and genotype 5 in three patients (2%).
The characteristics of these 299 patients did not differ from those of the 1726 patients of the whole series as far as gender, age, proportion of genotype 1 versus nongenotype 1 and proportion of transfused patients versus non-transfused patients were considered. Actually, 176 patients (59%) were not treated ( Table 1 ).
The reasons for not fulfilling therapy criteria were: normal ALT levels (n = 43, 24%), non-adherence to evaluation procedures (n = 44, 25%) and medical contraindications (n = 60, 34%). The medical contraindications were: psychiatric (n = 16, 27%), age (n = 13, 22%), endstage liver disease (n = 9, 15%), willingness of pregnancy (n = 8, 13%), significant coronary artery disease (n = 4, 7%), neoplasm other than hepatocellular carcinoma (n = 4, 7%), haematological disturbances (n = 3, 5%), autoimmune disease (n = 2, 3%) and retinopathy (n = 1, 1%). The psychiatric factors included: alcohol abuse (n = 4), current or recent drug abuse (n = 6), current or recent depressive symptoms (n = 4) and other psychiatric disorders (n = 4) including bipolar disorder or schizophrenia. The median age of patients excluded from therapy due to their age was 71 years (64-82 years). These patients were considered too old to be treated on a case-by-case decision.
Despite being considered eligible for treatment, 17% (n = 29) of patients declined therapy. Personal circumstances (e.g. currently in school, in search of a new job, living most of the time abroad) were the reasons to delay treatment in a few patients (n = 3). In most cases (n = 26), however, the patient's decision to delay therapy was the fear of adverse events. These 26 patients, theoretically eligible but who refused therapy, did not differ from the 123 patients who accepted therapy as far as gender, risk factors for HCV acquisition, genotype or stage of fibrosis were considered ( Table 2 ). They were, however, slightly older (47 ± 13 versus 41 ± 14 years, P = 0.026) than patients who accepted therapy. Although most refusals could not be considered a priori as definitive, no patient who initially refused to be treated changed his or her mind even after some years of followup and despite the improvement in the efficacy of therapies.
Eventually, only 123 patients (41%) were treated. The treatment regimens documented during the 7-year period included interferon and ribavirin or pegylated interferon and ribavirin. A sustained viral response was obtained in 41% of patients. The treatment was interrupted in 16% because of side effects.
Discussion
Combination therapy of peginterferon alfa-2a or alfa-2b together with ribavirin has significantly advanced the treatment of chronic hepatitis C and represents the current standard of care. Several large randomized clinical trials have demonstrated that the majority of patients achieve a sustained viral response with this combination therapy [19] [20] [21] . However, it appears that in the United States only a small proportion of infected patients benefit from these therapies. Rowan et al. [13] in a series of 580 Veterans, and Muir and Provenzale [12] in a series of 100 Veterans, showed that 70% and 68%, respectively, of their HCV patients had not been considered as eligible for therapy. Rocca et al. [17] retrospectively reviewed a series of 366 HCV patients listed in the Olmsted County Hepatitis C registry. For these patients, a discussion on treatment was performed for only 234 patients (64%). Among them, 179 (77%) remained finally untreated. In a series of 293 viraemic patients attending a teaching county hospital, Falck-Ytter et al. [15] showed that the rate of non-treatment was 72%. The populations of these series, however, were particular, with high proportions of African-Americans (24-51%) and intravenous drug users (43-74%) ( Table 3 ). It was postulated that these American series could not be compared with the population of patients seen in Europe. Epidemiological characteristics and risk factors in our series of patients attending a Belgian academic hospital effectively differed from those of the American series, while being very close to those observed in France in a cohort of 1872 patients [22] (Table 3) . Although there were statistically less drug users in our series than in this latter series, the distribution of risk factors in our series did not differ significantly from that described in another French cohort of 6664 patients [23] : 37% of transfusion-related transmission (versus 43% in our series) and 25% of drug addicts (versus 22%).
We found that most (59%) patients evaluated for a treatment were actually not treated. Although we treated significantly more patients than in the aforementioned American series (Table 3 ) (probably in relation to the academic nature of our hospital [16] and also to the difference in patients' characteristics), a majority of patients were considered non-eligible for therapy.
The most frequent reasons for not treating were medical contraindications, normal transaminases or refusal of therapy by the patient. Among motives for not initiating a treatment, 34/176 (19%) were definitive (end-stage liver disease, cardiac contraindications, leucopenia, age, retinopathy, neoplasia). The others could either be improved (non-compliance, refusal to be treated, drug abuse), be transient (pregnancy) or be related to guidelines' criteria (normal ALT). The recent demonstration, indeed, that the therapy is as effective in patients with normal ALT as in patients with elevated transaminases [24] probably will increase the rate of eligible patients.
The most frequent reason for the patient refusing therapy was the fear of potential adverse events. Neither the results of genotype determination nor of liver biopsy were predictive of acceptation of therapy in patients theoretically eligible for therapy ( Table 2 ). The sideeffect profile of peginterferon versus non-pegylated interferon being quite similar, it is not surprising that most patients who initially refused therapy maintained their position over the 7 years of this study despite the demonstration during these past years of an increased probability of sustained viral response afforded by peginterferon. The side effect profile of the current regimen of treatment of hepatitis C thus remains a serious barrier to therapy.
The overall rate of sustained viral response (41%) observed in the treated patients from 1996 to 2003 was very similar to that (40%) observed in academic hospitals from 1997 to 2001 in the United States [25] . The rate of discontinuation of treatment (16%) was also similar to those observed in registration trials of pegylated interferon and ribavirin [5, 26] . This means that only 50 patients out of 299 referred for chronic hepatitis C (17%) became sustained responders, a figure very close to what has been reported in a teaching county hospital in the United States (13%) [15] .
In real life, the majority of patients with chronic hepatitis C are not eligible for interferon plus ribavirin-based therapies. An important barrier to treatment remains the safety profile of these therapies. That emphasizes the need to continue to explore alternative treatment options or strategies for these patients. NS S, significant difference with the Belgian series at the P < 0.05 level; na, data not available. Patients in the US series were older and more likely to be African-Americans and intravenous drug users than those in the Belgian series. The proportion of untreated patients was higher in the US series. Belgian patients were, on the contrary, similar to French patients as far as age, ethnic origin or genotype distribution were concerned.
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